N Sundaresha Subramanian And Reghu Balakrishnan

Stories by N Sundaresha Subramanian And Reghu Balakrishnan

Russian financial scheme for rural India

Russian financial scheme for rural India

Rediff.com   6 Apr 2013

This financial scheme is based on a virtual currency and is propagated by Russian businessman and financier Sergey Mavrodi.

BDR wrestles Big Pharma in patents match

BDR wrestles Big Pharma in patents match

Rediff.com   3 Apr 2013

Compulsory licence application filed for anti-cancer drug of Bristol Myers Squibb; more to come for four drugs.

The man behind Glivec hails verdict against Novartis

The man behind Glivec hails verdict against Novartis

Rediff.com   3 Apr 2013

Brian Druker, who invented the drug's molecule, says it would benefit patients in the short term.

Domestic pharma lauds apex court verdict

Domestic pharma lauds apex court verdict

Rediff.com   2 Apr 2013

Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up.

Pvt infra firms may get to issue tax-free bonds

Pvt infra firms may get to issue tax-free bonds

Rediff.com   18 Mar 2013

Allocation to be need-based, track record of the issuer to be considered.

Investors run background checks on PE fund managers

Investors run background checks on PE fund managers

Rediff.com   22 Feb 2013

In some cases fake degrees and certificates were uncovered.

Proxy advisory firm against TVS scion's board entry

Proxy advisory firm against TVS scion's board entry

Rediff.com   22 Feb 2013

Though academically well qualified, doesn't have enough experience, says the firm.

E-retailers stare at bleak funding scenario

E-retailers stare at bleak funding scenario

Rediff.com   21 Feb 2013

As funding from foreign private equity and venture capital firms is the lifeline for most online retailers, the restriction on foreign direct investment is threatening to block any fresh investment into the sector.

'Time has now come to say GOODBYE to India'

'Time has now come to say GOODBYE to India'

Rediff.com   11 Feb 2013

Interview with Chairman, Cipla.

Indian majors lead race for US drug ingredient market

Indian majors lead race for US drug ingredient market

Rediff.com   30 Jan 2013

In 2012, drugs worth $35 billion went off-patent in the US, while the market size of drugs which will see patent expiry in 2013 will halve to $17 billion.

Fresh financial planners foxed by Sebi rules

Fresh financial planners foxed by Sebi rules

Rediff.com   29 Jan 2013

Many fresh pass-outs of the CFP course are faced with up to a two-year delay and thousands of rupees in fees for realisation of their dream, following the notification of new regulations. Sebi notified the Investment Advisers Regulations, 2013, earlier this month.

HUL's royalty increase catches flak

HUL's royalty increase catches flak

Rediff.com   23 Jan 2013

HUL's board approved the royalty of 3.15 per cent of turnover effective from February 2013.

Smart investors make 'dirty' gains in tax-free bonds

Smart investors make 'dirty' gains in tax-free bonds

Rediff.com   23 Jan 2013

Last year, the government had allowed NHAI, IRFC, Hudco, REC and PFC to issue tax-free bonds.

Investment banking: High profile exits continue

Investment banking: High profile exits continue

Rediff.com   21 Jan 2013

Past two years have witnessed a churn, mainly in the area of mergers and acquisitions.

Drug pricing: Govt decides to bypass three patents

Drug pricing: Govt decides to bypass three patents

Rediff.com   15 Jan 2013

The plan is to issue CLs for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia).

Bonds hauled in TN to be flown to US for verification

Bonds hauled in TN to be flown to US for verification

Rediff.com   11 Jan 2013

He had revealed confessional statements of three individuals who had used the services of a foreign bank to stash money abroad.

Rs 100-cr CSR bill likely for each of top-15 BSE cos

Rs 100-cr CSR bill likely for each of top-15 BSE cos

Rediff.com   3 Jan 2013

In first year, ONGC spending likely at Rs 405 cr, followed by Reliance Industries' at Rs 377 crore.

Essel Group enters i-banking, PE space

Essel Group enters i-banking, PE space

Rediff.com   31 Dec 2012

Sets up new financial services arm, Amit Goenka joins as CEO.

Investor protection to get a big boost

Investor protection to get a big boost

Rediff.com   20 Dec 2012

Class action, whistleblower protection and exit option likely to bring back investor confidence.

Mohan Meakin eyes mineral water comeback

Mohan Meakin eyes mineral water comeback

Rediff.com   18 Dec 2012

Golden Eagle was first launched 12 years ago, but the Ghaziabad-headquartered company stopped marketing the product a few years ago, to focus totally on its alcoholic division.